利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

12 条记录 (耗时 0.039 秒)

    Method for the treatment of skin fibrosis and suitable compositions for such treatment
    7.
    发明授权
    Method for the treatment of skin fibrosis and suitable compositions for such treatment 失效
    用于治疗皮肤纤维化的方法和用于这种治疗的合适的组合物

    公开(公告)号：US07582609B2

    公开(公告)日：2009-09-01

    申请号：US11365764

    申请日：2006-03-01

    申请人： Francisco Borras Cuesta ,  Javier Dotor De Las Herrerias ,  Juan Manuel Irache Garreta ,  Fernando Martinez Galan ,  Jesus Prieto Valtuena

    发明人： Francisco Borras Cuesta ,  Javier Dotor De Las Herrerias ,  Juan Manuel Irache Garreta ,  Fernando Martinez Galan ,  Jesus Prieto Valtuena

    IPC分类号： A61K9/107 ,  A61K38/08 ,  A61K38/10

    CPC分类号： A61K38/10 ,  Y10S514/937

    摘要： A Method for the treatment of skin fibrosis with a peptide that inhibits TGF-β, and suitable compositions for its administration. The method includes in particular, the use of peptide P144, a compound that is a known inhibitor of TGF-β, for the treatment of skin fibrosis by topical application. The method is shown effective in an animal model of bleomycin-induced skin sclerosis, to a reduction both of the skin fibrosis and of the content of soluble collagen, without any signs of systemic toxicity being detected. This shows that P144 is effective for topical application in mammals for treating fibrotic skin diseases and pathological scarring of the skin. For the administration of this peptide, stable compositions are also supplied, with pleasant appearance without being greasy, with good spreading characteristics and with a viscosity that permits it to be processed easily in industrial plant, and which are suitable for administering the peptide to humans.

    摘要翻译： 用抑制TGF-β的肽治疗皮肤纤维化的方法及其给药的合适组合物。 该方法特别包括使用肽P144，一种已知的TGF-β抑制剂的化合物，用于通过局部应用治疗皮肤纤维化。 该方法显示在博来霉素诱导的皮肤硬化的动物模型中有效，可以减少皮肤纤维化和可溶性胶原含量，而没有检测到任何全身毒性迹象。 这表明P144在哺乳动物中用于治疗纤维化皮肤疾病和皮肤病理性瘢痕形成的局部应用是有效的。 对于该肽的给药，还提供了稳定的组合物，具有愉悦的外观，而不油腻，具有良好的铺展特性，并且具有允许其在工业植物中容易加工的粘度，并且适合于向人体施用肽。

    Pegylated Nanoparticles
    8.
    发明申请
    Pegylated Nanoparticles 有权
    聚乙二醇化纳米粒子

    公开(公告)号：US20080248125A1

    公开(公告)日：2008-10-09

    申请号：US11568454

    申请日：2005-04-28

    申请人： Juan Manuel Irache Garreta ,  Krassimira Pavlova Yoncheva

    发明人： Juan Manuel Irache Garreta ,  Krassimira Pavlova Yoncheva

    IPC分类号： A61K9/51

    CPC分类号： A61K9/14 ,  A61K9/5138 ,  A61K9/5146 ,  A61K9/5192 ,  A61K47/6933 ,  C08F222/06 ,  Y10S977/773

    摘要： The present invention relates to nanoparticles comprising a biodegradable polymer, preferably the vinyl methyl ether and maleic anhydride (PVM/MA) copolymer, and a polyethylene glycol or derivatives thereof. These nanoparticles are easy to produce and provide excellent bioadhesion, size and zeta potential characteristics making them suitable for the administration of active molecules. The selection of the type of polyethylene glycol used in their production allows suitably modulating the characteristics of these nanoparticles, which can be advantageously used according to the type of drug to be carried and/or the method of administration of the pharmaceutical formulation. pegylation is carried out by simple incubation for a short time period of the two macromolecules in question, without needing to have to resort to the use of organic solvents with high toxicity or long and laborious organic synthesis processes. Furthermore, the pegylation process can be associated to the process of encapsulating the biologically active molecule.

    摘要翻译： 本发明涉及包含生物可降解聚合物，优选乙烯基甲基醚和马来酸酐（PVM / MA）共聚物的纳米颗粒，以及聚乙二醇或其衍生物。 这些纳米颗粒易于生产，并提供优异的生物粘附，尺寸和ζ电位特性，使其适合于施用活性分子。 在其生产中使用的聚乙二醇的类型的选择允许适当地调节这些纳米颗粒的特性，其可以根据待携带的药物的类型和/或药物制剂的施用方法有利地使用。 聚乙二醇化是通过简单孵育所述两个大分子的短时间进行的，而不需要使用具有高毒性或长时间和费力的有机合成方法的有机溶剂。 此外，聚乙二醇化方法可以与封装生物活性分子的过程相关。

    Pegylated nanoparticles
    9.
    发明授权
    Pegylated nanoparticles 有权
    聚乙二醇化纳米粒子

    公开(公告)号：US08628801B2

    公开(公告)日：2014-01-14

    申请号：US11568454

    申请日：2005-04-28

    申请人： Juan Manuel Irache Garreta ,  Krassimira Pavlova Yoncheva

    发明人： Juan Manuel Irache Garreta ,  Krassimira Pavlova Yoncheva

    IPC分类号： A61K9/14 ,  C08F222/06 ,  A61K8/81

    CPC分类号： A61K9/14 ,  A61K9/5138 ,  A61K9/5146 ,  A61K9/5192 ,  A61K47/6933 ,  C08F222/06 ,  Y10S977/773

    摘要： The present invention relates to nanoparticles comprising a biodegradable polymer, preferably the vinyl methyl ether and maleic anhydride (PVM/MA) copolymer, and a polyethylene glycol or derivatives thereof. These nanoparticles are easy to produce and provide excellent bioadhesion, size and zeta potential characteristics making them suitable for the administration of active molecules. The selection of the type of polyethylene glycol used in their production allows suitably modulating the characteristics of these nanoparticles, which can be advantageously used according to the type of drug to be carried and/or the method of administration of the pharmaceutical formulation. pegylation is carried out by simple incubation for a short time period of the two macromolecules in question, without needing to have to resort to the use of organic solvents with high toxicity or long and laborious organic synthesis processes. Furthermore, the pegylation process can be associated to the process of encapsulating the biologically active molecule.

    摘要翻译： 本发明涉及包含生物可降解聚合物，优选乙烯基甲基醚和马来酸酐（PVM / MA）共聚物的纳米颗粒，以及聚乙二醇或其衍生物。 这些纳米颗粒易于生产，并提供优异的生物粘附，尺寸和ζ电位特性，使其适合于施用活性分子。 在其生产中使用的聚乙二醇的类型的选择允许适当地调节这些纳米颗粒的特性，其可以根据待携带的药物的类型和/或药物制剂的施用方法有利地使用。 聚乙二醇化是通过简单孵育所述两个大分子的短时间进行的，而不需要使用具有高毒性或长时间和费力的有机合成方法的有机溶剂。 此外，聚乙二醇化方法可以与封装生物活性分子的过程相关。